Neuphoria Therapeutics Inc.
NEUPHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeNeuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in. Valued at $18.1M, NEUP is a micro-cap name in its sector. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.
Market Cap
$18.1M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.37
EPS (TTM)
$-8.04
EPS (Fwd)
$-2.43
ROE
-62.9%
ROA
-28.0%
Cash
$19.4M
Total Debt
$34,225
Free CF
-$10.2M
52W Change
-56.6%
Annual Financials
Cash vs Debt
Where NEUP stands vs its 150-day and 200-day moving averages
As of the July 14, 2026 close, NEUP finished 20.68% below its 150-day moving average ($4.40) and 36.55% below its 200-day moving average ($5.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NEUP overbought or oversold?
At the July 14, 2026 close, NEUP's RSI(14) was 27.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $19.4M in cash comfortably exceeding the $34K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$10.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -62.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, NEUP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Neuphoria Therapeutics Inc. and its sector.